- Home
- DSGN vs UHG Comparison
DSGN vs UHG Comparison
Compare DSGN & UHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- UHG
- Stock Information
- Founded
- DSGN 2017
- UHG 2004
- Country
- DSGN United States
- UHG United States
- Employees
- DSGN N/A
- UHG N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- UHG Homebuilding
- Sector
- DSGN Health Care
- UHG Consumer Discretionary
- Exchange
- DSGN Nasdaq
- UHG Nasdaq
- Market Cap
- DSGN 208.9M
- UHG 205.1M
- IPO Year
- DSGN 2021
- UHG N/A
- Fundamental
- Price
- DSGN $3.77
- UHG $2.85
- Analyst Decision
- DSGN Hold
- UHG
- Analyst Count
- DSGN 1
- UHG 0
- Target Price
- DSGN $4.00
- UHG N/A
- AVG Volume (30 Days)
- DSGN 82.2K
- UHG 218.7K
- Earning Date
- DSGN 08-04-2025
- UHG 08-07-2025
- Dividend Yield
- DSGN N/A
- UHG N/A
- EPS Growth
- DSGN N/A
- UHG N/A
- EPS
- DSGN N/A
- UHG 0.76
- Revenue
- DSGN N/A
- UHG $449,877,017.00
- Revenue This Year
- DSGN N/A
- UHG N/A
- Revenue Next Year
- DSGN N/A
- UHG N/A
- P/E Ratio
- DSGN N/A
- UHG $3.74
- Revenue Growth
- DSGN N/A
- UHG 5.24
- 52 Week Low
- DSGN $2.60
- UHG $1.60
- 52 Week High
- DSGN $7.77
- UHG $6.93
- Technical
- Relative Strength Index (RSI)
- DSGN 49.66
- UHG 46.12
- Support Level
- DSGN $3.33
- UHG $2.62
- Resistance Level
- DSGN $4.21
- UHG $3.93
- Average True Range (ATR)
- DSGN 0.24
- UHG 0.36
- MACD
- DSGN -0.02
- UHG -0.13
- Stochastic Oscillator
- DSGN 50.29
- UHG 17.56
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.